19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 3
SP-43-COVID-19 in pregnant women
event_note Saturday, 24 Oct 2020
query_builder 12:30 - 13:50 | Event time (GMT+1)
query_builder 12:30 - 13:50 | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-43-COVID-19 in pregnant women
*Please scroll down for more information*
Immunologic and physiologic changes occur rapidly in pregnancy and may impact pathogenesis, clinical presentation and transmission of SARS-CoV-2, complicating management and leading to poor maternal-foetal outcomes in some cases. Recent reports of asymptomatic women admitted for delivery services have led some settings to initiate universal screening. This symposium will feature emerging research on the immunology of COVID-19 in pregnancy and the differences in clinical presentation and management - including treatment options, policies for safe pregnancy and potential research priorities - which will improve our understanding of this devastating pandemic in all populations.

12:30 - 12:35: Introduction

12:35 - 12:45: Pathogenesis and immunology of COVID-19 in pregnant womenThe Washington State COVID-19 in Pregnancy Collaborative was established to identify known pregnant COVID-19 cases from 16 major tertiary referral centres and community hospitals representing >40% of the ~86,000 annual deliveries in Washington State. In order to improve our understanding of how SARS-CoV-2, the virus that causes COVID-19 impacts the health of pregnant women and their newborns, a multipronged approach is needed, including population-based efforts to describe pregnancy outcomes among women with COVID-19, as well as detailed immunologic studies including placental innate immune responses to SARS-CoV-2. We will discuss the pathogenesis and immunology of COVID-19 in pregnancy, including lessons learned from other emerging infectious diseases.
Kristina Adams Waldorf

12:45 - 12:55: Pregnancy and postpartum outcomes of COVID-19 in New York City: a multicentre prospective cohort studyOver 700,000 confirmed cases of SARS-CoV-2 and 20,000 deaths from COVID-19 have occurred in New York City, making it the epicentre of the infection with fatalities topping that of many European countries. Early in the pandemic, pregnant women were noted to be asymptomatic carriers of SARS-CoV-2, and New York rapidly instated a universal screening programme. In this talk, the findings from this prospective cohort will be discussed, including maternal presentation, obstetric and neonatal outcomes, and placental pathology associated with COVID-19 infection. We will also discuss the evolution of maternal symptoms throughout the course of labour and the postpartum period, with implications for postpartum care.
Malavika Prabhu

12:55 - 13:05: Use of remdesivir for moderate to severe COVID-19 in pregnancyRemdesivir is one of the promising treatments being investigated for the treatment of COVID-19. Gilead, the manufacturer of remdesivir, allowed compassionate use of remdesivir for pregnant women with moderate to severe COVID-19. In this talk, they will present the experience of 86 pregnant women, who received compassionate-use remdesivir, including baseline demographic and clinical characteristics, their time to recovery and time to discharge. For women who delivered, birth outcomes and postpartum complications will be characterised. This data will be important groundwork for future clinical trials that include pregnant women.
Moupali Das

13:05 - 13:15: Crowd-sourcing knowledge for COVID-19 in pregnancy with the World Health Organization registry: potential for maternal TB and beyond?To understand how SARS-CoV-2 infection during pregnancy impacts COVID and pregnancy and postpartum outcomes, the World Health Organization (WHO) has developed a standardised clinical registration platform with a specific module targeting pregnant women. Further, a standardised research protocol has been designed. The protocol allows each site to adapt, based on resource availability and local circumstances, and provides the option to focus on national analyses or participate in pooling. Knowledge of tuberculosis (TB) in pregnancy is still scarce. This presentation will discuss possibilities to build on experiences through different methods related to SARS-CoV-2 and possible implication to TB.
Anna Thorson

13:15 - 13:50: Q&A session

Loading...
Processing. Please wait.
Loading...